Targeted Therapies in RA: Real World Comparative Effectiveness Research
dc.contributor.author | Harrold, Leslie R. | |
dc.date | 2022-08-11T08:08:12.000 | |
dc.date.accessioned | 2022-08-23T15:46:14Z | |
dc.date.available | 2022-08-23T15:46:14Z | |
dc.date.issued | 2011-05-20 | |
dc.date.submitted | 2011-08-04 | |
dc.identifier.doi | 10.13028/wfmt-nv05 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14038/27707 | |
dc.description.abstract | The objective of this study was to compare the effectiveness of abatacept to anti-TNFs using the following: Change in disease activity based on the Clinical Disease Activity Index, and (CDAI) Achievement of remission based on the CDAI. Among this small sample of RA patients in a real-world setting, treatment with abatacept was not associated with any differences in response or remission rates from those seen with anti-TNFs based on mean change in CDAI and achievement of CDAI remission. This study suggests similar effectiveness of abatacept and anti-TNFs in biologic naïve RA patients. Further research with a larger sample size is needed to confirm these findings. | |
dc.format | youtube | |
dc.language.iso | en_US | |
dc.rights | Copyright the Author(s) | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/3.0/ | |
dc.subject | Analytical, Diagnostic and Therapeutic Techniques and Equipment | |
dc.subject | Rheumatology | |
dc.subject | Therapeutics | |
dc.title | Targeted Therapies in RA: Real World Comparative Effectiveness Research | |
dc.type | Presentation | |
dc.identifier.legacyfulltext | https://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1003&context=cts_retreat&unstamped=1 | |
dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/cts_retreat/2011/presentations/3 | |
dc.identifier.contextkey | 2132937 | |
refterms.dateFOA | 2022-08-23T15:46:14Z | |
html.description.abstract | <p>The objective of this study was to compare the effectiveness of abatacept to anti-TNFs using the following: Change in disease activity based on the Clinical Disease Activity Index, and (CDAI) Achievement of remission based on the CDAI.</p> <p>Among this small sample of RA patients in a real-world setting, treatment with abatacept was not associated with any differences in response or remission rates from those seen with anti-TNFs based on mean change in CDAI and achievement of CDAI remission. This study suggests similar effectiveness of abatacept and anti-TNFs in biologic naïve RA patients. Further research with a larger sample size is needed to confirm these findings.</p> | |
dc.identifier.submissionpath | cts_retreat/2011/presentations/3 |